Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 4/2017

01-08-2017 | Original Research Article

Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus

Authors: Anna Rydén, Stephanie Chen, Emuella Flood, Beverly Romero, Susan Grandy

Published in: The Patient - Patient-Centered Outcomes Research | Issue 4/2017

Login to get access

Abstract

Introduction

Methods for discrete choice experiment (DCE) attribute and attribute-level selection have not yet been firmly established and are rarely reported in detail. This paper describes a qualitative study designed to inform the development of a DCE survey designed to examine preferences for glucagon-like peptide-1 receptor agonist (GLP-1RA) treatments among patients with type 2 diabetes mellitus.

Methods

The study involved a literature review, interviews with clinical experts, and interviews with GLP-1RA-experienced (i.e., exenatide once weekly, liraglutide once daily) and injection-naïve type 2 diabetes patients from Brazil, China, Germany, Japan, and the UK. Interviews followed a semi-structured guide including open-ended questions, and probes to capture the patients’ perspective on important aspects of GLP-1RAs and concerns with injectable treatments. Qualitative analyses were performed utilizing MAXQDA version 11. Descriptive statistics were used to summarize the sample.

Results

Thirty-two articles were reviewed, including 13 DCE studies. Thirty-one attributes were identified from the DCE studies, and 61 different attributes were identified in the non-DCE studies. Fifty patients completed interviews: 28 (56%) GLP-1RA-experienced and 22 (44%) injection-naïve, 54% were male, and they had a mean age of 52.8 years. Patients considered efficacy, adverse effects, and dosing frequency as the most important treatment-related attributes. From a list of five pre-defined device- or regimen-related attributes, patients considered dosing frequency, needle size, and injection preparation as the three most important attributes.

Conclusion

This study adds to the DCE literature to inform researchers on attribute selection methodology in an international setting as there is limited published information to guide researchers on best practices for selecting and defining attributes for DCE surveys.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coast J, Al-Janabi H, Sutton EJ, Horrocks AS, Vosper AJ, Swancutt DR, et al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21:730–41.CrossRef Coast J, Al-Janabi H, Sutton EJ, Horrocks AS, Vosper AJ, Swancutt DR, et al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21:730–41.CrossRef
2.
go back to reference American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9.CrossRef American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9.CrossRef
3.
go back to reference Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clin Diabetes. 2012;30(1):3–12.CrossRef Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clin Diabetes. 2012;30(1):3–12.CrossRef
4.
go back to reference Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004;7(4):442–54.CrossRef Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004;7(4):442–54.CrossRef
5.
go back to reference Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark—a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83.CrossRef Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark—a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83.CrossRef
6.
go back to reference Guimarães C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients’ willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66.CrossRef Guimarães C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients’ willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66.CrossRef
7.
go back to reference Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.CrossRef Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.CrossRef
8.
go back to reference Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. J Med Econ. 2012;15(Suppl 2):1–5.CrossRef Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. J Med Econ. 2012;15(Suppl 2):1–5.CrossRef
9.
go back to reference Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson A, Bøgelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23.CrossRef Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson A, Bøgelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23.CrossRef
10.
go back to reference Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67.CrossRef Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67.CrossRef
11.
go back to reference Mohamed AF, Zhang J, Johnson FR, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403.CrossRef Mohamed AF, Zhang J, Johnson FR, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403.CrossRef
12.
go back to reference Mühlbacher AC, Bethge S, Kaczynski A, Juhnke C. Patients preferences regarding the treatment of type II diabetes mellitus: comparison of best-worst scaling and analytic hierarchy process. Value Health. 2013;16(7):A446.CrossRef Mühlbacher AC, Bethge S, Kaczynski A, Juhnke C. Patients preferences regarding the treatment of type II diabetes mellitus: comparison of best-worst scaling and analytic hierarchy process. Value Health. 2013;16(7):A446.CrossRef
13.
go back to reference Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.CrossRef Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.CrossRef
14.
go back to reference Ridderstråle M, Torffvit O, Lammert M, Nilsen B, Jendle J. Patient willingness to pay for liraglutide and exenatide in Sweden based on head-to-head clinical trial results [abstract]. Diabetologia. 2009;52:S550.CrossRef Ridderstråle M, Torffvit O, Lammert M, Nilsen B, Jendle J. Patient willingness to pay for liraglutide and exenatide in Sweden based on head-to-head clinical trial results [abstract]. Diabetologia. 2009;52:S550.CrossRef
15.
go back to reference Yang M, Lin P, Wintfeld N, Frois C. Effect of diabetes patient characteristics on the willingness-to-pay for a new basal insulin—a discrete choice experiment [abstract no. PDB80]. Value Health. 2012;15(4):A185.CrossRef Yang M, Lin P, Wintfeld N, Frois C. Effect of diabetes patient characteristics on the willingness-to-pay for a new basal insulin—a discrete choice experiment [abstract no. PDB80]. Value Health. 2012;15(4):A185.CrossRef
16.
go back to reference Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013;35(7):923–33.CrossRef Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013;35(7):923–33.CrossRef
17.
go back to reference Clark PE, Valentine V, Bodie JN, Sarwat S. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens. Curr Med Res Opin. 2010;26(7):1745–53.CrossRef Clark PE, Valentine V, Bodie JN, Sarwat S. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens. Curr Med Res Opin. 2010;26(7):1745–53.CrossRef
18.
go back to reference Hancu N, Czupryniak L, Genestin E, Sourij H. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol. 2011;5(5):1224–34.CrossRef Hancu N, Czupryniak L, Genestin E, Sourij H. A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol. 2011;5(5):1224–34.CrossRef
19.
go back to reference Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35(5):789–98.CrossRef Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35(5):789–98.CrossRef
20.
go back to reference Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012;28(1):3–13.CrossRef Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012;28(1):3–13.CrossRef
21.
go back to reference Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011;8(10):1259–69.CrossRef Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011;8(10):1259–69.CrossRef
22.
go back to reference Pfützner A, Schipper C, Niemeyer M, Qvist M, Löffler A, Forst T, et al. Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol. 2012;6(4):910–6.CrossRef Pfützner A, Schipper C, Niemeyer M, Qvist M, Löffler A, Forst T, et al. Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol. 2012;6(4):910–6.CrossRef
23.
go back to reference Schipper C, Musholt P, Niemeyer M, Qvist M, Löffler A, Forst T, et al. Patient device assessment evaluation of two insulin injection devices in a mixed cohort of insulin-treated patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2012;28(8):1297–303.CrossRef Schipper C, Musholt P, Niemeyer M, Qvist M, Löffler A, Forst T, et al. Patient device assessment evaluation of two insulin injection devices in a mixed cohort of insulin-treated patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2012;28(8):1297–303.CrossRef
24.
go back to reference Toscano D, Brice J, Alfaro C. Usage and perceptions of pen injectors for diabetes management: a survey of type 2 diabetes patients in the United States. J Diabetes Sci Technol. 2012;6(3):686–94.CrossRef Toscano D, Brice J, Alfaro C. Usage and perceptions of pen injectors for diabetes management: a survey of type 2 diabetes patients in the United States. J Diabetes Sci Technol. 2012;6(3):686–94.CrossRef
25.
go back to reference Harshaw Q, Peyrot M, Shillington AC, Xu Y, Rubin RR. Diabetes medication treatment satisfaction in adults with type 2 diabetes [abstract no. 833-P]. American Diabetes Association 71st Scientific Sessions, 24–28 June 2011, San Diego. Harshaw Q, Peyrot M, Shillington AC, Xu Y, Rubin RR. Diabetes medication treatment satisfaction in adults with type 2 diabetes [abstract no. 833-P]. American Diabetes Association 71st Scientific Sessions, 24–28 June 2011, San Diego.
26.
go back to reference Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med. 2011;28(6):715–23.CrossRef Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med. 2011;28(6):715–23.CrossRef
27.
go back to reference Newton C, Ivie E, Smiley D, Cardona S, Mejia R, Umpierrez G. Greater satisfaction and less hypoglycemia among elderly patients with insulin using pens [abstract no. 804-P]. American Diabetes Association 73rd Scientific Sessions, 21–25 June 2013, Chicago. Newton C, Ivie E, Smiley D, Cardona S, Mejia R, Umpierrez G. Greater satisfaction and less hypoglycemia among elderly patients with insulin using pens [abstract no. 804-P]. American Diabetes Association 73rd Scientific Sessions, 21–25 June 2013, Chicago.
28.
go back to reference Miao R, Wei W, Lin J, Xie L, Baser O. Does device make any difference? A real-world retrospective study of insulin treatment among elderly patients with type 2 diabetes. J Diabetes Sci Technol. 2014;8(1):150–8.CrossRef Miao R, Wei W, Lin J, Xie L, Baser O. Does device make any difference? A real-world retrospective study of insulin treatment among elderly patients with type 2 diabetes. J Diabetes Sci Technol. 2014;8(1):150–8.CrossRef
29.
go back to reference Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5mm needles. Diabetes Technol Ther. 2009;11(2):81–6.CrossRef Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5mm needles. Diabetes Technol Ther. 2009;11(2):81–6.CrossRef
30.
go back to reference Brunton S, Gough S, Hicks D, Weng J, Moghissi E, Peyrot M, et al. A look into the future: improving diabetes care by 2015. Curr Med Res Opin. 2011;27(Suppl 3):65–72.CrossRef Brunton S, Gough S, Hicks D, Weng J, Moghissi E, Peyrot M, et al. A look into the future: improving diabetes care by 2015. Curr Med Res Opin. 2011;27(Suppl 3):65–72.CrossRef
31.
go back to reference Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.CrossRef Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.CrossRef
32.
go back to reference Hauber AB, Nguyen H, Posner J, Ervin CM, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes [abstract no. PDB102]. Value Health. 2014;17(3):A255.CrossRef Hauber AB, Nguyen H, Posner J, Ervin CM, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes [abstract no. PDB102]. Value Health. 2014;17(3):A255.CrossRef
33.
go back to reference Stauder U, Enginee D, Elton H, Penfornis A, Edelman S. Comparative assessment of lixisenatide, exenatide, and liraglutide pen devices: a pilot user-based study. J Diabetes Sci Technol. 2014;8(1):123–31.CrossRef Stauder U, Enginee D, Elton H, Penfornis A, Edelman S. Comparative assessment of lixisenatide, exenatide, and liraglutide pen devices: a pilot user-based study. J Diabetes Sci Technol. 2014;8(1):123–31.CrossRef
34.
go back to reference Abu Hassan H, Tohid H, Mohd Amin R, Long Bidin MB, Muthupalaniappen L, Omar K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013;29(14):164.CrossRef Abu Hassan H, Tohid H, Mohd Amin R, Long Bidin MB, Muthupalaniappen L, Omar K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013;29(14):164.CrossRef
35.
go back to reference Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, et al. Using exenatide twice daily or insulin in clinical practice: results from CHOICE. Diabetes Ther. 2013;4(2):285–308.CrossRef Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, et al. Using exenatide twice daily or insulin in clinical practice: results from CHOICE. Diabetes Ther. 2013;4(2):285–308.CrossRef
Metadata
Title
Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus
Authors
Anna Rydén
Stephanie Chen
Emuella Flood
Beverly Romero
Susan Grandy
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 4/2017
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-017-0225-0

Other articles of this Issue 4/2017

The Patient - Patient-Centered Outcomes Research 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine